Ingevity (NGVT) ends portfolio review and buys back over $30M in shares
Rhea-AI Filing Summary
Ingevity Corporation reported that it has completed its previously announced portfolio review and is exploring strategic alternatives for its Advanced Polymer Technologies segment and its Performance Chemicals Road Markings business. This means the company is formally assessing options such as potential sales, partnerships, or other structural changes for these operations.
The company also stated that, as part of its efforts to return meaningful capital to stockholders, it has completed over $30 million in stock repurchases during the fourth quarter of 2025. These buybacks reduce the number of shares in the market and represent a direct way of returning cash to shareholders.
Positive
- None.
Negative
- None.
Insights
Ingevity finishes portfolio review and repurchases over $30 million of stock in Q4 2025.
Ingevity Corporation has completed its portfolio review and is exploring strategic alternatives for its Advanced Polymer Technologies segment and Performance Chemicals Road Markings business. Exploring alternatives typically means evaluating options like divestitures, joint ventures, or other restructurings, which can reshape the company’s business mix if pursued.
The company also reports over
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM
CURRENT REPORT
Pursuant to Section 13 or 15 (d) of the Securities Exchange Act of 1934
Date of Report (date of earliest event reported)
(Exact name of registrant as specified in its charter)
(State or other jurisdiction of incorporation or organization) |
(Commission File Number) |
(I.R.S. Employer Identification No.) |
| (Address of principal executive offices) | (Zip code) |
Registrant’s
telephone number, including area code:
Not Applicable
(Former name or former address, if changed since last report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
| Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) | |
| Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) | |
| Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) | |
| Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Securities registered pursuant to Section 12(b) of the Act:
| Title of each class | Trading Symbol(s) | Name of each exchange on which registered | ||
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
| Emerging growth company |
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act ☐
ITEM 7.01. REGULATION fd DISCLOSURE
On December 8, 2025, Ingevity Corporation (the “Company”) issued a press release announcing the completion of the Company’s previously disclosed portfolio review process and its exploration of strategic alternatives for its Advanced Polymer Technologies segment and Performance Chemicals Road Markings business.
A copy of the press release announcing the completion of the portfolio review from the Company is furnished as Exhibit 99.1 to this Current Report on Form 8-K (this “Current Report”).
In connection with the Company’s efforts to return meaningful capital to its stockholders, the Company has (as of the date of this Current Report) completed over $30 million in stock repurchases during the fourth quarter of 2025.
The information furnished under Item 7.01 of this Current Report, including Exhibit 99.1 attached hereto, shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934 (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing by the Company under the Securities Act of 1933 or the Exchange Act, except as shall be expressly set forth by specific reference in such filing.
ITEM 9.01. FINANCIAL STATEMENTS AND EXHIBITS
(d) Exhibits.
| Exhibit No. | Description of Exhibit | |
| 99.1 | Press Release, dated December 8, 2025 | |
| 104 | Cover Page Interactive Data File (embedded within the Inline XBRL document) |
| 2 |
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
| INGEVITY CORPORATION | ||
| (Registrant) | ||
| By: | /s/ Mary Dean Hall | |
| Mary Dean Hall | ||
| Executive Vice President and Chief Financial Officer | ||
Date: December 8, 2025
| 3 |
FAQ
What did Ingevity Corporation (NGVT) announce in this 8-K filing?
Which Ingevity businesses are subject to strategic alternatives?
How much stock has Ingevity (NGVT) repurchased in Q4 2025?
What is the purpose of Ingevity’s recent stock repurchases?
Does this 8-K filing include the full details of Ingevity’s strategic alternatives?
Is the information in Ingevity’s press release considered filed with the SEC?
